Loading...
•
Jun 30, 2023
Onconova Q2 2023 Earnings Report
Reported second quarter 2023 financial results and provided an update on recent pipeline progress.
Key Takeaways
Onconova Therapeutics reported a net loss of $4.3 million, or $0.20 per share, for the second quarter of 2023. As of June 30, 2023, cash and cash equivalents were $29.7 million, expected to fund operations into the second quarter of 2024.
Anticipate topline results from the Phase 1 monotherapy and Phase 1/2 combination study with letrozole in Q4 2023.
Plans are underway for a registrational trial with rigosertib in patients with RDEB-associated squamous cell carcinoma based on a constructive Type B FDA meeting held in June.
Cash and cash equivalents as of June 30, 2023, were $29.7 million.
Net loss for the second quarter of 2023 was $4.3 million, or $0.20 per share.
Onconova
Onconova
Forward Guidance
The Company believes that its cash and cash equivalents will be sufficient to fund ongoing clinical trials and business into the second quarter of 2024.